LivaNova (NASDAQ:LIVN) PT Raised to $66.00 at Robert W. Baird

LivaNova (NASDAQ:LIVN) had its target price raised by Robert W. Baird from $58.00 to $66.00 in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other equities research analysts have also issued reports on LIVN. Barclays boosted their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a report on Monday, February 26th. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a research report on Thursday, April 25th. Mizuho lifted their price objective on LivaNova from $75.00 to $80.00 and gave the company a buy rating in a report on Thursday. Finally, Needham & Company LLC reissued a buy rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, LivaNova currently has a consensus rating of Moderate Buy and an average target price of $66.20.

LivaNova Stock Up 2.0 %

Shares of LIVN opened at $64.15 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.51 and a current ratio of 3.17. The company has a 50-day simple moving average of $54.71 and a 200-day simple moving average of $51.06. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.36. The firm has a market capitalization of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.45 by $0.28. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The firm had revenue of $294.90 million during the quarter, compared to analysts’ expectations of $278.17 million. During the same quarter in the prior year, the firm posted $0.43 EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, equities research analysts expect that LivaNova will post 3.01 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently bought and sold shares of the business. New York State Teachers Retirement System boosted its stake in LivaNova by 0.3% in the first quarter. New York State Teachers Retirement System now owns 64,322 shares of the company’s stock worth $3,598,000 after purchasing an additional 200 shares in the last quarter. Arizona State Retirement System lifted its position in LivaNova by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 15,309 shares of the company’s stock worth $810,000 after buying an additional 264 shares in the last quarter. State of Michigan Retirement System increased its position in LivaNova by 2.3% in the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock valued at $739,000 after acquiring an additional 300 shares in the last quarter. Louisiana State Employees Retirement System increased its position in LivaNova by 2.6% in the 1st quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company’s stock valued at $867,000 after acquiring an additional 400 shares in the last quarter. Finally, Headlands Technologies LLC raised its stake in shares of LivaNova by 33.3% in the fourth quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock worth $93,000 after acquiring an additional 451 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.